Septerna, Inc.

Septerna, Inc.

NNASDAQ:SEPN
41.67
USD
-0.93
(-2.18%)
-1.30EPS
1.86BMarket Cap
Apr 01Next Earn
Septerna, Inc.
NASDAQ:SEPN
(Nasdaq Stock Market)

Recent

price

41.67

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
USD
- -
0.01
0.11
1.04
2.12
Revenue per Share
-1.42
0.21
-7.26
-1.1
-1.3
Basic EPS, GAAP
-1.26
-2.13
-7.03
2.48
-1.71
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
-1.05
-0.91
9.46
8.52
9.03
Book Value per Share
-1.05
-0.91
9.46
8.52
9.03
Tangible Book Value per Share
19
19
10
44
45
Basic Weighted Avg Shares
- -
- -
1
46
96
Sales/Revenue/Turnover
- -
-30,165.56
-7,518.42
-175.83
-76.23
Operating Margin (%)
1
1
1
2
2
Depreciation Expense
-28
4
-72
-49
-59
Net Income, GAAP
- -
14.19
- -
- -
- -
Effective Tax Rate (%)
- -
2,768.21
-6,678.88
-106.37
-61.29
Profit Margin (%)
26
106
344
324
402
Working Capital
- -
13
24
21
19
LT Debt
-44
-38
420
382
428
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-12.06
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-12.19
-14.45
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
3
LT Borrowings
- -
- -
- -
LT Finance Leases
21
20
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
46
47
Market Capitalization
1,079
1,529
1,855

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
368
396
507
Cash, Cash Equivalents & STI
347
372
479
Accounts Receivable, Net
11
12
19
Inventories
- -
- -
- -
Total Current Liabilities
78
79
105
Payables & Accruals
13
14
21
ST Debt
2
2
3
Deferred Revenue
60
60
76

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-9.08%
Free Cash Flow
- -
- -
-257.63%
Net Income, GAAP
- -
- -
-31.92%
Sales/Revenue/Turnover
- -
- -
4,174.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
21
24
46
2026
27
27
19
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.34
-0.39
-0.49
-0.64
-7.26
2025
-0.49
-0.56
0.18
-0.24
-1.1
2026
-0.19
-0.29
-0.57
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company that discovers and develops oral small molecule therapeutics targeting G protein-coupled receptors (GPCRs) using its proprietary, industrial-scale Native Complex Platform. The company advances a wholly owned pipeline focused initially on endocrinology, immunology and inflammation, and metabolic diseases, including SEP-479, an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) for hypoparathyroidism; SEP-631, an oral small molecule negative allosteric modulator (NAM) of MAS-related G protein-coupled receptor X2 (MRGPRX2) for chronic spontaneous urticaria and other mast cell-driven diseases; and a TSHR program featuring an oral small molecule NAM of the thyroid-stimulating hormone receptor (TSHR) for Graves' disease and thyroid eye disease. Additional research areas span neurology, women's health, cardiovascular disease, and respiratory disease; partnered metabolic programs target obesity, type 2 diabetes, and other cardiometabolic conditions via small molecule agonists of GLP-1R, GIPR, and GCGR receptors. Septerna serves patients with significant unmet needs across these therapeutic segments through novel mechanistic approaches, including agonists, antagonists, and allosteric modulators enabled by biomarker-driven strategies. Founded in 2019 and headquartered in South San Francisco, California, the company--formerly known as GPCR NewCo, Inc., with a name change in June 2021--went public on Nasdaq in October 2024. In a major strategic development, Septerna entered a global collaboration with Novo Nordisk in May 2025 to discover, develop, and commercialize multiple oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases targeting specified GPCR targets including GLP-1, GIP, and glucagon receptors; the agreement provides over $200 million in upfront and near-term payments, potential milestones exceeding $2.2 billion, tiered royalties on global net sales, and an option for Septerna to participate in worldwide profit-sharing for one program, with Novo Nordisk funding all research and development expenses post-IND-enabling activities for partnered programs. Recent pipeline progress includes dosing of the first participants in the Phase 1 clinical trial of SEP-631 in 2025 and advancement of SEP-479 and TSHR programs toward clinical stages, alongside reporting third quarter 2025 financial results that highlight a cash position extended beyond early 2028. Septerna operates primarily from the United States with no disclosed subsidiaries or parent entities.

Company News

  • Septerna, Inc. (SEPN) Presents at UBS Global Biopharma Conference 2026 Transcript

  • Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?

  • Septerna: The SEP-479 Readout Could Unlock Further Upside

  • Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates

  • Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results

  • Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

  • Septerna to Participate in Upcoming Investor Conferences

  • Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares of Stock

  • CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head Survey

  • Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)

  • Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)

  • VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 13,300 Septerna, Inc. $SEPN

  • Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • Septerna to Participate in Upcoming Investor Conferences

  • Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term

  • Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

  • Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

  • Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

  • Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

  • Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting